Trial ID: | L0869 |
Source ID: | NCT02145325
|
Associated Drug: |
Expanded Tregs
|
Title: |
Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients
|
Acronym: |
TRACT
|
Status: |
COMPLETED
|
Study Results: |
NO
|
Results: |
|
Conditions: |
End Stage Renal Disease
|
Interventions: |
DRUG: Expanded Tregs
|
Outcome Measures: |
Primary: Safety Profile Assessment of TRACT, The primary safety endpoint is the evaluation of cellular related toxicities immediately and within 24 hrs post infusion of TRACT. Since TRACT is being administered to promote immunosuppression and prevent rejection, specific adverse events (subsequent rejection episodes, allosensitization, development of opportunistic infection) within 30 days of infusion will be monitored., 5 years (60 weeks) |
|
Sponsor/Collaborators: |
Sponsor: Northwestern University
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE1
|
Enrollment: |
10
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
Start Date: |
2014-04
|
Completion Date: |
2016-06-16
|
Results First Posted: |
|
Last Update Posted: |
2019-10-08
|
Locations: |
Northwestern University Comprehensive Transplant Center, Chicago, Illinois, 60611, United States
|
URL: |
https://clinicaltrials.gov/show/NCT02145325
|